- Home
- HBCP vs NGNE Comparison
HBCP vs NGNE Comparison
Compare HBCP & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBCP
- NGNE
- Stock Information
- Founded
- HBCP 1908
- NGNE 2003
- Country
- HBCP United States
- NGNE United States
- Employees
- HBCP N/A
- NGNE N/A
- Industry
- HBCP Banks
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- HBCP Finance
- NGNE Health Care
- Exchange
- HBCP Nasdaq
- NGNE Nasdaq
- Market Cap
- HBCP 431.6M
- NGNE 213.2M
- IPO Year
- HBCP 2008
- NGNE N/A
- Fundamental
- Price
- HBCP $55.77
- NGNE $21.32
- Analyst Decision
- HBCP Buy
- NGNE Strong Buy
- Analyst Count
- HBCP 2
- NGNE 7
- Target Price
- HBCP $57.50
- NGNE $41.86
- AVG Volume (30 Days)
- HBCP 73.9K
- NGNE 223.5K
- Earning Date
- HBCP 07-21-2025
- NGNE 08-08-2025
- Dividend Yield
- HBCP 1.93%
- NGNE N/A
- EPS Growth
- HBCP 0.90
- NGNE N/A
- EPS
- HBCP 4.78
- NGNE N/A
- Revenue
- HBCP $135,421,000.00
- NGNE $925,000.00
- Revenue This Year
- HBCP $0.25
- NGNE N/A
- Revenue Next Year
- HBCP $5.18
- NGNE N/A
- P/E Ratio
- HBCP $11.73
- NGNE N/A
- Revenue Growth
- HBCP 3.44
- NGNE N/A
- 52 Week Low
- HBCP $37.35
- NGNE $6.88
- 52 Week High
- HBCP $56.94
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- HBCP 69.66
- NGNE 61.90
- Support Level
- HBCP $55.01
- NGNE $19.98
- Resistance Level
- HBCP $56.80
- NGNE $18.21
- Average True Range (ATR)
- HBCP 1.31
- NGNE 1.71
- MACD
- HBCP 0.31
- NGNE 0.39
- Stochastic Oscillator
- HBCP 94.23
- NGNE 90.54
About HBCP Home Bancorp Inc.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities. The principal sources of funds are customer deposits, repayments of loans, repayments of investments and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.